Treatment of COVID-19 Patients by Glucocorticoids: Which Dose? Which Type? A Single- Center Cohort Study

When a virus like SARS-CoV-2 invades the body, the immune system sometimes overreacts, launching a chaotic and damaging assault on the lungs known as a cytokine storm. This excessive inflammation can be just as dangerous as the virus itself, leading to severe breathing difficulties and organ failure. For years, doctors have turned to a class of powerful anti-inflammatory drugs called glucocorticoids to calm this storm. These medications, which include familiar names like dexamethasone and prednisolone, act like a heavy hand on the immune system's accelerator, slowing down the destructive response. While major clinical trials have confirmed that these drugs save lives in severe cases, a lingering question remained: does it matter exactly which type of steroid a doctor chooses, or how much of it a patient receives? Finding the right balance is critical, because too little might fail to stop the inflammation, while too much could suppress the immune system so thoroughly that it invites new infections or other complications.

In a large study conducted at a single hospital in Tehran, Iran, researchers set out to explore these questions by looking back at the records of over 5,000 patients hospitalized with confirmed COVID-19 and lung involvement. The team examined how the total amount of different steroids given to each patient during their stay related to their final outcome. They focused on three specific types of glucocorticoids: methylprednisolone, dexamethasone, and prednisolone. By analyzing the cumulative doses—meaning the total sum of the medication a patient received from admission to discharge—the researchers tried to see if higher amounts of a specific drug were linked to living or dying, staying in the hospital longer, or having better or worse lung scans. It is important to note that this was an observational study, meaning the doctors chose the treatments based on what they thought was best for each patient at the time, rather than assigning drugs randomly. This approach allows researchers to spot patterns in real-world practice, though it requires careful interpretation to avoid mistaking correlation for cause.

The results revealed a distinct pattern depending on which drug was used. For patients who received methylprednisolone, the data suggested that those who received higher total doses were less likely to die in the hospital. Specifically, for every increase of 100 milligrams in the total amount of methylprednisolone given, the odds of death decreased. This finding aligns with the idea that this particular steroid might be especially effective at controlling the severe inflammation seen in critical cases. However, the story was different for the other two drugs. Patients who received higher total doses of dexamethasone or prednisolone tended to stay in the hospital longer. The researchers found that for every 10-milligram increase in the total dexamethasone dose, the hospital stay extended by a noticeable amount, and a similar, though smaller, effect was seen with prednisolone. This does not necessarily mean the drugs caused the longer stays; rather, it likely reflects that the sickest patients, who were already expected to have a longer and more difficult recovery, were the ones who received the highest doses of these medications.

Perhaps the most surprising and cautious finding involved the lung scans. While the study found no clear link between the dose of methylprednisolone and how much the lung damage improved on a CT scan, a higher total dose of dexamethasone was actually associated with less radiological improvement. In other words, patients who received more dexamethasone tended to have lung scans that showed persistent or worsening cloudiness compared to those who received less. The researchers offered several possible reasons for this counterintuitive result. It could be that the patients receiving the most dexamethasone were simply the ones with the most aggressive and resistant disease. Alternatively, the strong immune-suppressing effects of high doses might have allowed the virus to linger longer or led to secondary infections that kept the lungs inflamed. The authors emphasized that this specific finding is paradoxical and requires further investigation, as it might be a statistical artifact of the severity of the illness rather than a direct effect of the drug.

The study concluded with a strong warning against changing medical practice based solely on these numbers. Because the researchers could not control which drug or dose a patient received, and because the sickest patients naturally received more treatment, the data is best viewed as a set of hypotheses for future testing rather than a definitive rulebook. The team noted that while the link between higher methylprednisolone doses and lower death rates is encouraging, it needs to be confirmed in randomized trials where patients are assigned to specific treatments by chance. Similarly, the observation that higher doses of dexamethasone and prednisolone were linked to longer hospital stays and less lung improvement serves as a signal to be cautious about high-dose regimens, but it does not prove that reducing the dose would help. Ultimately, the study reinforces that while glucocorticoids are a cornerstone of treating severe COVID-19, the optimal type and amount remain complex questions that require more rigorous, controlled research to answer with certainty.